DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2026)

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The type 2 diabetes therapy market will steadily expand over our 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the most rapid growth are the sodium/glucose cotransporter 2 (SGLT 2) inhibitors—due to the cardiovascular (CV) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 (GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.

QUESTIONS ANSWERED

  • Following Jardiance’s positive CV results, will SGLT 2 inhibitors surpass the dipeptidyl peptidase (DPP) IV inhibitors as the most valuable oral drug class?
  • Boosted by positive CV data, will Victoza continue to lead the GLP 1 receptor agonists in the face of once-weekly agents such as Trulicity and Ozempic?
  • Will investments by the pharmaceutical industry in novel FDCs such as Xultophy and Soliqua reap rewards?
  • What do key opinion leaders think about emerging therapies such as sotagliflozin, ITCA-650, and oral semaglutide?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • April 2019
      • March 2019
      • December 2018
      • August 2018
      • June 2018
    • Market Outlook
      • Market Outlook
        • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Type 2 Diabetes?
        • What Factors Are Constraining the Market for Type 2 Diabetes?
      • Drug-Class-Specific Trends
        • DPP-IV Inhibitors
        • SGLT-2 Inhibitors
        • DPP-IV/SGLT-2 Inhibitors
        • GLP-1 Receptor Agonists
        • Long-Acting Insulin Analogues
        • Rapid-Acting Insulin Analogues
        • Long-Acting Insulin/GLP-1 Receptor Agonist Fixed-Dose Combinations
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Disease Overview
        • Etiology
        • Pathophysiology
        • Disease Progression
        • Key Pathways and Drug Targets
    • Epidemiology
      • Introduction
        • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases
        • Diagnosed Prevalent Cases of Type 2 Diabetes
        • Drug-Treated Cases of Type 2 Diabetes
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • DPP-IV Inhibitors
        • GLP-1 Receptor Agonists
        • SGLT-2 Inhibitors
        • Biguanides
        • Sulfonylureas
        • Thiazolidinediones
        • Long-Acting Insulins
        • Short- and Intermediate-Acting Insulins
        • Rapid-Acting Insulins
        • DPP-IV/SGLT-2 Inhibitor Fixed-Dose Combinations
      • Medical Practice
        • Overview
        • Drug Selection
        • Region-Specific Treatment
    • Unmet Need Overview
      • Attainment of Unmet Needs
        • Current and Future Attainment of Unmet Needs in Type 2 Diabetes
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments in the Late-Phase Pipeline for Type 2 Diabetes
        • SGLT-2 Inhibitors
        • DPP-IV/SGLT-2 Inhibitor Fixed-Dose Combinations
        • GLP-1 Receptor Agonists
        • Rapid-Acting Insulin Analogues
        • Premixed Insulins
        • Long-Acting Insulin/GLP-1 Receptor Agonist Fixed-Dose Combinations
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Type 2 Diabetes
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
        • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Type 2 Diabetes Bibliography

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): David Rees, Ph.D; Amy Bradshaw Kaiser, MS
  • David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.

  • Amy Kaiser joined Decision Resources Group as an associate epidemiologist in 2017. Her focus is on the epidemiology of infectious diseases and niche and rare diseases. She holds an MS in Epidemiology from the University of Massachusetts, Amherst and a BA in International Relations from Mount Holyoke College. Prior to joining Decision Resources Group, she worked as a human health research associate at a environmental consulting firm where her epidemiology research focused on occupational and environmental exposures and associated outcomes.

Purchase Report

Recent reports:
You may also be interested in: